S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Akebia Wins Vafseo Patent Expiring in 2043

A new Akebia Therapeutics patent covering the use of Vafseo in managing drug interactions runs until Jan. 18, 2043, extending protection beyond 14 other listed patents for vadadustat, the drug’s generic name.

Issued Tuesday, the patent covers a method of treatment involving the modulation of drug-drug interactions during treatment with vadadustat. The other 14 patents listed for the drug have expiration dates ranging from 2027 to 2036.

The Food and Drug Administration approved Vafseo in March 2024 to treat anemia due to chronic kidney disease. The drug has been available in the United States since January 2025.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!